APA (7th ed.) Citation

JF, S., K, C., N, K., S, A., G, N., J, C., . . . JA, R. (2025). Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: Single ascending dose and multiple ascending dose trial data. ImmunoHorizons, 9(5), . https://doi.org/10.1093/immhor/vlaf005

Chicago Style (17th ed.) Citation

JF, Scheid, et al. "Safety, Pharmacokinetics, and Pharmacodynamics of MK-6194, an IL-2 Mutein Designed to Selectively Activate Regulatory T Cells: Single Ascending Dose and Multiple Ascending Dose Trial Data." ImmunoHorizons 9, no. 5 (2025). https://doi.org/10.1093/immhor/vlaf005.

MLA (9th ed.) Citation

JF, Scheid, et al. "Safety, Pharmacokinetics, and Pharmacodynamics of MK-6194, an IL-2 Mutein Designed to Selectively Activate Regulatory T Cells: Single Ascending Dose and Multiple Ascending Dose Trial Data." ImmunoHorizons, vol. 9, no. 5, 2025, https://doi.org/10.1093/immhor/vlaf005.